Dermapharm Holding SE
XETRA:DMP
Intrinsic Value
Dermapharm Holding SE engages in the development, manufacture and market of patent-free pharmaceutical products. [ Read More ]
The intrinsic value of one
DMP
stock under the Base Case scenario is
36.78
EUR.
Compared to the current market price of 31.5 EUR,
Dermapharm Holding SE
is
Undervalued by 14%.
Dermapharm Holding SE's market capitalization is 1.7B EUR.
DMP stock price is 31.5 EUR.
DMP stock price (31.5 EUR) is 14% less than its Intrinsic Value (36.78 EUR).
DMP has upside potential of 83% compared to the average analyst price target.
Open Wall St Estimates
DMP's ROE (Return on Equity) for the past 12 months is positive and is equal to 12%.
DMP's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 7%.
DMP's Revenue is forecast to grow at a rate of 4% per year over the next 3 years.
DMP's Revenue has grown by 11% over the past 12 months.
DMP's ROIC (Return on Invested Capital) has decreased in the last 3 years from 11% to 7%.
DMP has positive Net Income for the last twelve months.
DMP has positive three-year average ROIC (Return on Invested Capital): 13%. The company is efficient at using invested capital to generate operating income.
DMP's long-term assets (2B EUR) exceed its long-term liabilties (2B EUR).
DMP's Revenue has been growing by 13% per year for the last 3 years.
DMP's short-term assets (630m EUR) exceed its short-term liabilties (394m EUR).
DMP has positive Operating Income for the last twelve months.
DMP's ROE (Return on Equity) has significantly decreased in the last 3 years from 29% to 12%.
DMP's D/E (Debt to Equity) is equal to 1.79.
DMP's Altman Z-Score is equal to 1.97.
DMP has positive Free Cash Flow for the last twelve months.
DMP has positive Gross Profit for the last twelve months.
DMP has very high three-year average ROE (Return on Equity): 33%. The company is very efficient at transforming stockholders' equity into net income.
DMP has positive Net Debt. This means that the company has more debt (964m EUR) than cash and short-term investments (162m EUR).
DMP generates enough operating income (201m EUR) to cover interest payments on its debt (33m EUR).
Valuation Backtest
Dermapharm Holding SE
Run backtest to discover the historical profit from buying and selling
DMP
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Dermapharm Holding SE
Balance Sheet Decomposition
Dermapharm Holding SE
| Current Assets | 630.5m |
| Cash & Short-Term Investments | 162.5m |
| Receivables | 91.1m |
| Other Current Assets | 376.9m |
| Non-Current Assets | 1.5B |
| Long-Term Investments | 76m |
| PP&E | 330.8m |
| Intangibles | 1.1B |
| Other Non-Current Assets | 2k |
| Current Liabilities | 394.5m |
| Accounts Payable | 86.6m |
| Short-Term Debt | 8k |
| Other Current Liabilities | 307.8m |
| Non-Current Liabilities | 1.2B |
| Long-Term Debt | 964m |
| Other Non-Current Liabilities | 263m |
Earnings Waterfall
Dermapharm Holding SE
|
Revenue
|
1.1B
EUR
|
|
Cost of Revenue
|
-416.2m
EUR
|
|
Gross Profit
|
719.2m
EUR
|
|
Operating Expenses
|
-518.2m
EUR
|
|
Operating Income
|
201m
EUR
|
|
Other Expenses
|
-138.6m
EUR
|
|
Net Income
|
62.4m
EUR
|
Free Cash Flow Analysis
Dermapharm Holding SE
DMP Profitability Score
Profitability Due Diligence
Dermapharm Holding SE's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Score
Dermapharm Holding SE's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
DMP Solvency Score
Solvency Due Diligence
Dermapharm Holding SE's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
Dermapharm Holding SE's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DMP Price Targets Summary
Dermapharm Holding SE
According to Wall Street analysts, the average 1-year price target for
DMP
is 57.63 EUR
with a low forecast of 48.48 EUR and a high forecast of 68.25 EUR.
Shareholder Return
DMP Price
Dermapharm Holding SE
| Average Annual Return | 19.75% |
| Standard Deviation of Annual Returns | 51.8% |
| Max Drawdown | -64% |
| Market Capitalization | 1.7B EUR |
| Shares Outstanding | 53 840 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Dermapharm Holding SE
Country
Industry
Market Cap
Dividend Yield
Description
Dermapharm Holding SE engages in the development, manufacture and market of patent-free pharmaceutical products. The company is headquartered in Gruenwald, Bayern and currently employs 2,373 full-time employees. The company went IPO on 2018-02-09. The firm operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. The company holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The firm offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. The company is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Contact
IPO
Employees
Officers
The intrinsic value of one
DMP
stock under the Base Case scenario is
36.78
EUR.
Compared to the current market price of 31.5 EUR,
Dermapharm Holding SE
is
Undervalued by 14%.
You don't have any saved screeners yet
